D
Agios Pharmaceuticals, Inc.
AGIO
$25.87
-$1.84-6.64%
D
Sell
3/21/2025Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 3/21/2025 due to a decline in the volatility index and total return index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 3/21/2025 due to a decline in the volatility index and total return index.
C
Hold
2/14/2025Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D- on 2/14/2025 due to a significant increase in the valuation index, efficiency index and total return index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D- on 2/14/2025 due to a significant increase in the valuation index, efficiency index and total return index.
D
Sell
8/24/2023Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 8/24/2023 due to an increase in the volatility index and total return index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 8/24/2023 due to an increase in the volatility index and total return index.
E
Sell
8/8/2023Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 8/8/2023 due to a decline in the solvency index and volatility index. The quick ratio declined from 16.43 to 12.78.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 8/8/2023 due to a decline in the solvency index and volatility index. The quick ratio declined from 16.43 to 12.78.
D
Sell
8/3/2023Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 8/3/2023 due to an increase in the volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 8/3/2023 due to an increase in the volatility index.
E
Sell
7/18/2023Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 7/18/2023 due to a decline in the volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 7/18/2023 due to a decline in the volatility index.
D
Sell
6/30/2023Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 6/30/2023 due to an increase in the total return index and volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 6/30/2023 due to an increase in the total return index and volatility index.
E
Sell
6/14/2023Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 6/14/2023 due to a decline in the volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 6/14/2023 due to a decline in the volatility index.
D
Sell
5/24/2023Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 5/24/2023 due to an increase in the volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D- from E+ on 5/24/2023 due to an increase in the volatility index.
E
Sell
5/9/2023Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index and total return index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index and total return index.
D
Sell
5/8/2023Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 5/8/2023 due to a large decline in the efficiency index and valuation index. Net income declined 321.81% from $36.53M to -$81.02M, and total capital declined 5.7% from $1.19B to $1.12B.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 5/8/2023 due to a large decline in the efficiency index and valuation index. Net income declined 321.81% from $36.53M to -$81.02M, and total capital declined 5.7% from $1.19B to $1.12B.
D
Sell
8/8/2022Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 8/8/2022 due to a noticeable increase in the growth index, efficiency index and volatility index. Total revenue increased 570.91% from $832 to $5.58M, operating cash flow increased 24.05% from -$97.74M to -$74.23M, and earnings per share increased from -$1.7372 to -$1.6753.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 8/8/2022 due to a noticeable increase in the growth index, efficiency index and volatility index. Total revenue increased 570.91% from $832 to $5.58M, operating cash flow increased 24.05% from -$97.74M to -$74.23M, and earnings per share increased from -$1.7372 to -$1.6753.
D
Sell
5/6/2022Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 5/6/2022 due to a significant decline in the valuation index, growth index and total return index. Operating cash flow declined 16.22% from -$84.09M to -$97.74M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 5/6/2022 due to a significant decline in the valuation index, growth index and total return index. Operating cash flow declined 16.22% from -$84.09M to -$97.74M.
D
Sell
12/10/2021Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 12/10/2021 due to a decline in the total return index and volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 12/10/2021 due to a decline in the total return index and volatility index.
D
Sell
11/8/2021Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D+ from D on 11/8/2021 due to a major increase in the growth index, total return index and solvency index. Operating cash flow increased 27.38% from -$117.29M to -$85.18M, and EBIT increased 0.08% from -$91.22M to -$91.15M.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D+ from D on 11/8/2021 due to a major increase in the growth index, total return index and solvency index. Operating cash flow increased 27.38% from -$117.29M to -$85.18M, and EBIT increased 0.08% from -$91.22M to -$91.15M.
D
Sell
9/15/2021Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 9/15/2021 due to a decline in the volatility index and total return index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 9/15/2021 due to a decline in the volatility index and total return index.
D
Sell
8/2/2021Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 8/2/2021 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from $26.9518 to -$1.4118, and EBIT declined 0.01% from -$91.22M to -$91.22M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 8/2/2021 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from $26.9518 to -$1.4118, and EBIT declined 0.01% from -$91.22M to -$91.22M.
C
Hold
6/21/2021Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D+ on 6/21/2021 due to an increase in the total return index and volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D+ on 6/21/2021 due to an increase in the total return index and volatility index.
D
Sell
5/3/2021Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D+ from D on 5/3/2021 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 2,019.29% from -$97.66M to $1.87B, and total capital increased 213.36% from $765.97M to $2.4B.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D+ from D on 5/3/2021 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 2,019.29% from -$97.66M to $1.87B, and total capital increased 213.36% from $765.97M to $2.4B.
D
Sell
5/1/2020Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 5/1/2020 due to a significant increase in the growth index and valuation index. Total revenue increased 145.76% from $35.44M to $87.1M, earnings per share increased from -$1.6005 to -$0.5868, and EBIT increased 59.23% from -$105.93M to -$43.19M.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 5/1/2020 due to a significant increase in the growth index and valuation index. Total revenue increased 145.76% from $35.44M to $87.1M, earnings per share increased from -$1.6005 to -$0.5868, and EBIT increased 59.23% from -$105.93M to -$43.19M.
D
Sell
11/6/2018Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 11/6/2018 due to a large decline in the total return index, efficiency index and volatility index. Net income declined 37.7% from -$68.75M to -$94.66M, and total capital declined 7.64% from $823.14M to $760.21M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 11/6/2018 due to a large decline in the total return index, efficiency index and volatility index. Net income declined 37.7% from -$68.75M to -$94.66M, and total capital declined 7.64% from $823.14M to $760.21M.
D
Sell
5/7/2018Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 5/7/2018 due to a large increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.5 to 10.54.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 5/7/2018 due to a large increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.5 to 10.54.
D
Sell
3/21/2017Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 3/21/2017 due to a decline in the valuation index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 3/21/2017 due to a decline in the valuation index.
D
Sell
3/6/2017Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 3/6/2017 due to an increase in the volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 3/6/2017 due to an increase in the volatility index.
D
Sell
2/17/2017Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 2/17/2017 due to a decline in the efficiency index and solvency index. The quick ratio declined from 7.53 to 6.18, and total capital declined 10.68% from $401.45M to $358.59M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 2/17/2017 due to a decline in the efficiency index and solvency index. The quick ratio declined from 7.53 to 6.18, and total capital declined 10.68% from $401.45M to $358.59M.
D
Sell
11/4/2016Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 11/4/2016 due to an increase in the efficiency index, growth index and volatility index. Total capital increased 38.87% from $289.08M to $401.45M, and total revenue increased 28.76% from $6.98M to $8.99M.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 11/4/2016 due to an increase in the efficiency index, growth index and volatility index. Total capital increased 38.87% from $289.08M to $401.45M, and total revenue increased 28.76% from $6.98M to $8.99M.
D
Sell
8/10/2016Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 8/10/2016 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 141.2% from -$23.2M to -$55.95M, total capital declined 13.03% from $332.37M to $289.08M, and the quick ratio declined from 7.1 to 7.04.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 8/10/2016 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 141.2% from -$23.2M to -$55.95M, total capital declined 13.03% from $332.37M to $289.08M, and the quick ratio declined from 7.1 to 7.04.
D
Sell
3/11/2016Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Operating cash flow declined 23.03% from -$24.82M to -$30.53M, EBIT declined 1.05% from -$40.48M to -$40.9M, and earnings per share declined from -$1.0733 to -$1.0831.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Operating cash flow declined 23.03% from -$24.82M to -$30.53M, EBIT declined 1.05% from -$40.48M to -$40.9M, and earnings per share declined from -$1.0733 to -$1.0831.
D
Sell
8/10/2015Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 8/10/2015 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 115.56% from -$25.59M to $3.98M, total revenue declined 61.35% from $34.2M to $13.22M, and total capital declined 5.31% from $426.82M to $404.17M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 8/10/2015 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 115.56% from -$25.59M to $3.98M, total revenue declined 61.35% from $34.2M to $13.22M, and total capital declined 5.31% from $426.82M to $404.17M.
C
Hold
7/27/2015Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D+ on 7/27/2015 due to a noticeable increase in the volatility index and growth index. Operating cash flow increased 229.07% from -$7.78M to -$25.59M, and total revenue increased 133.68% from $14.64M to $34.2M.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D+ on 7/27/2015 due to a noticeable increase in the volatility index and growth index. Operating cash flow increased 229.07% from -$7.78M to -$25.59M, and total revenue increased 133.68% from $14.64M to $34.2M.
D
Sell
2/27/2015Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 2/27/2015 due to a decline in the total return index, efficiency index and growth index. EBIT declined 933.14% from $3.21M to -$26.73M, earnings per share declined from $0.1 to -$0.7592, and net income declined 819.87% from $3.7M to -$26.66M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D+ from C- on 2/27/2015 due to a decline in the total return index, efficiency index and growth index. EBIT declined 933.14% from $3.21M to -$26.73M, earnings per share declined from $0.1 to -$0.7592, and net income declined 819.87% from $3.7M to -$26.66M.
C
Hold
11/10/2014Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D on 11/10/2014 due to a large increase in the total return index, efficiency index and volatility index. Total capital increased 3.59% from $200.55M to $207.75M.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to C- from D on 11/10/2014 due to a large increase in the total return index, efficiency index and volatility index. Total capital increased 3.59% from $200.55M to $207.75M.
D
Sell
7/15/2014Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 7/15/2014 due to an increase in the valuation index and volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from D- on 7/15/2014 due to an increase in the valuation index and volatility index.
D
Sell
6/30/2014Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 6/30/2014 due to a decline in the valuation index.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D- from D on 6/30/2014 due to a decline in the valuation index.
D
Sell
5/12/2014Downgrade
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 5/12/2014 due to a decline in the efficiency index. Total capital declined 7.71% from $131.48M to $121.34M, and net income declined 1.08% from -$12.38M to -$12.25M.
Agios Pharmaceuticals, Inc. (AGIO) was downgraded to D from D+ on 5/12/2014 due to a decline in the efficiency index. Total capital declined 7.71% from $131.48M to $121.34M, and net income declined 1.08% from -$12.38M to -$12.25M.
D
Sell
3/26/2014Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D+ from D on 3/26/2014 due to a noticeable increase in the total return index and volatility index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D+ from D on 3/26/2014 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/6/2014Upgraded
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from E+ on 3/6/2014 due to a large increase in the volatility index, total return index and growth index.
Agios Pharmaceuticals, Inc. (AGIO) was upgraded to D from E+ on 3/6/2014 due to a large increase in the volatility index, total return index and growth index.
NASDAQ
04/04/2025 12:57PM Eastern
Quotes delayed
